WO2001057081A3 - Nouveaux homologues de type subtilase (narc-1) - Google Patents

Nouveaux homologues de type subtilase (narc-1) Download PDF

Info

Publication number
WO2001057081A3
WO2001057081A3 PCT/US2001/003976 US0103976W WO0157081A3 WO 2001057081 A3 WO2001057081 A3 WO 2001057081A3 US 0103976 W US0103976 W US 0103976W WO 0157081 A3 WO0157081 A3 WO 0157081A3
Authority
WO
WIPO (PCT)
Prior art keywords
polynucleotides
polypeptides
invention further
protein
relates
Prior art date
Application number
PCT/US2001/003976
Other languages
English (en)
Other versions
WO2001057081A2 (fr
Inventor
Lillian Wei-Ming Chiang
Original Assignee
Millennium Pharm Inc
Chiang Lillian Wei Ming
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc, Chiang Lillian Wei Ming filed Critical Millennium Pharm Inc
Priority to AU2001241461A priority Critical patent/AU2001241461A1/en
Priority to EP01912710A priority patent/EP1257572A2/fr
Priority to CA002399727A priority patent/CA2399727A1/fr
Publication of WO2001057081A2 publication Critical patent/WO2001057081A2/fr
Publication of WO2001057081A3 publication Critical patent/WO2001057081A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une nouvelle protéine de mort cellulaire programmée (PCD) humaine et de souris présentant une homologie avec des subtilases mammifères. L'invention concerne également des polynucléotides codant pour ces protéines et des méthodes utilisant ces polypeptides et ces polynucléotides comme cibles pour le diagnostic et le traitement de troubles induits par cette protéine ou liés à celle-ci. L'invention se rapporte enfin à des méthodes de criblage de médicament utilisant ces polypeptides et ces polynucléotides pour identifier des agonistes et des antagonistes en vue d'un diagnostic et d'un traitement, à des agonistes et des antagonistes basés sur ces polypeptides et ces polynucléotides, et à des opérations destinées à produire lesdits polypeptides et polynucléotides.
PCT/US2001/003976 2000-02-07 2001-02-07 Nouveaux homologues de type subtilase (narc-1) WO2001057081A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2001241461A AU2001241461A1 (en) 2000-02-07 2001-02-07 Narc-1, novel subtilase-like homologs
EP01912710A EP1257572A2 (fr) 2000-02-07 2001-02-07 Nouveaux homologues de type subtilase (narc-1)
CA002399727A CA2399727A1 (fr) 2000-02-07 2001-02-07 Nouveaux homologues de type subtilase (narc-1)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49923500A 2000-02-07 2000-02-07
US09/499,235 2000-02-07
US51790600A 2000-03-03 2000-03-03
US09/517,906 2000-03-03

Publications (2)

Publication Number Publication Date
WO2001057081A2 WO2001057081A2 (fr) 2001-08-09
WO2001057081A3 true WO2001057081A3 (fr) 2002-03-14

Family

ID=27053087

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/003976 WO2001057081A2 (fr) 2000-02-07 2001-02-07 Nouveaux homologues de type subtilase (narc-1)

Country Status (4)

Country Link
EP (1) EP1257572A2 (fr)
AU (1) AU2001241461A1 (fr)
CA (1) CA2399727A1 (fr)
WO (1) WO2001057081A2 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859741B2 (en) 2007-08-23 2014-10-14 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8999341B1 (en) 2014-07-15 2015-04-07 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9062105B1 (en) 2014-07-15 2015-06-23 Kymab Limited Precision Medicine by targeting VEGF-A variants for treatment of retinopathy
US9109034B1 (en) 2014-07-15 2015-08-18 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9266961B2 (en) 2012-06-15 2016-02-23 Genentech, Inc. Anti-PCSK9 antibodies, formulations, dosing, and methods of use

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003106667A2 (fr) * 2002-06-12 2003-12-24 Bayer Healthcare Ag Regulation d'une serine protease de type subtilase humaine
EP1471152A1 (fr) 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations du gène humain PCSK9 qui sont associées à la hypercholesterolemia
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EP2444494B1 (fr) 2006-10-09 2016-09-28 Roche Innovation Center Copenhagen A/S Composés antagonistes de l'arn pour la modulation de pcsk9
JP5588175B2 (ja) 2006-11-07 2014-09-10 メルク・シャープ・アンド・ドーム・コーポレーション Ｐｃｓｋ９のアンタゴニスト
CA2680832A1 (fr) 2007-03-27 2008-10-02 Merck & Co., Inc. Procede de detection de pcsk9 secretee, autogeneree
CN101679527A (zh) * 2007-04-13 2010-03-24 诺瓦提斯公司 用于调节前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)的分子和方法
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
WO2010068526A1 (fr) 2008-12-12 2010-06-17 Merck Sharp & Dohme Corp. Immunodosage de pcsk9
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8357371B2 (en) 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
WO2011009697A1 (fr) 2009-07-21 2011-01-27 Santaris Pharma A/S Oligomères anti-sens ciblant pcsk9
AU2010313381A1 (en) 2009-10-30 2012-04-12 Merck Sharp & Dohme Corp. AX1 and AX189 PCSK9 antagonists and variants
CN102639150A (zh) 2009-10-30 2012-08-15 默沙东公司 Ax213和ax132 pcsk9拮抗剂和变体
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
AR084938A1 (es) 2011-01-28 2013-07-10 Sanofi Sa Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
AU2012308797B2 (en) 2011-09-16 2017-06-01 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PSCK9)
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US9540449B2 (en) 2012-08-13 2017-01-10 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
KR20160024906A (ko) 2013-06-07 2016-03-07 사노피 바이오테크놀로지 Ｐｃｓｋ9의 억제제를 투여함에 의한 죽상경화증의 억제 방법
EP3591054A1 (fr) 2013-06-27 2020-01-08 Roche Innovation Center Copenhagen A/S Oligomères et conjugués antisens ciblant pcsk9
EP3882273A1 (fr) 2013-11-12 2021-09-22 Sanofi Biotechnology Schémas posologiques pour une utilisation avec des inhibiteurs de pcsk9
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
GB2521355A (en) * 2013-12-17 2015-06-24 Kymab Ltd Human targets I
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR20170029613A (ko) 2014-07-16 2017-03-15 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
EP3337828A1 (fr) 2015-08-18 2018-06-27 Regeneron Pharmaceuticals, Inc. Anticorps inhibiteurs anti-pcsk9 destinés au traitement des patients atteints d'hyperlipidémie subissant une aphérèse de lipoprotéines
WO2018083248A1 (fr) 2016-11-03 2018-05-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
AU2017382323B2 (en) 2016-12-23 2024-06-13 President And Fellows Of Harvard College Gene editing of PCSK9
WO2019041066A1 (fr) * 2017-08-26 2019-03-07 深圳市博奥康生物科技有限公司 Construction d'un vecteur d'expression eucaryote fh3 et préparation d'une souche cellulaire à haute expression à l'aide de celui-ci
WO2021207711A2 (fr) 2020-04-09 2021-10-14 Verve Therapeutics, Inc. Arn guides modifiés chimiquement pour l'édition du génome avec cas9

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1067182A2 (fr) * 1999-07-08 2001-01-10 Helix Research Institute Proteine secretoire ou proteine de membrane
WO2001031007A2 (fr) * 1999-10-22 2001-05-03 Millennium Pharmaceuticals, Inc. Molecules d'acide nucleique derivees d'un cerveau de rat et modeles de mort cellulaire programmee

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1067182A2 (fr) * 1999-07-08 2001-01-10 Helix Research Institute Proteine secretoire ou proteine de membrane
WO2001031007A2 (fr) * 1999-10-22 2001-05-03 Millennium Pharmaceuticals, Inc. Molecules d'acide nucleique derivees d'un cerveau de rat et modeles de mort cellulaire programmee

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BARTON A J L ET AL: "Identification of genes differentially expressed between HT-4 clones selected for resistance or sensitivity to glutamate mediated oxidative toxicity.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 24, no. 1-2, 1998, 28th Annual Meeting of the Society for Neuroscience, Part 1;Los Angeles, California, USA; November 7-12, 1998, pages 232, XP001027885, ISSN: 0190-5295 *
CHIANG LILLIAN W ET AL: "An orchestrated gene expression component of neuronal programmed cell death revealed by cDNA array analysis.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 98, no. 5, 27 February 2001 (2001-02-27), February 27, 2001, pages 2814 - 2819, XP002178543, ISSN: 0027-8424 *
DATABASE EMBL [online] 11 September 1997 (1997-09-11), XP002178545, Database accession no. AA552314 *
DATABASE EMBL [online] 23 August 1999 (1999-08-23), XP002178546, Database accession no. AI952478 *
DATABASE EMBL [online] 4 August 1999 (1999-08-04), XP002178544, Database accession no. AI940122 *
DATABASE EMBL 30 May 2001 (2001-05-30) *
MILLER TIMOTHY M ET AL: "Metabolic and genetic analyses of apoptosis in potassium/serum-deprived rat cerebellar granule cells.", JOURNAL OF NEUROSCIENCE, vol. 16, no. 23, 1996, pages 7487 - 7495, XP002178541, ISSN: 0270-6474 *
MUNRO G K L ET AL: "A GENE ENCODING A THERMOPHILIC ALKALINE SERINE PROTEINASE FROM THERMUS SP. STRAIN RT41A AND ITS EXPRESSION IN ESCHERICHIA COLI", MICROBIOLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, GB, vol. 141, no. PART 7, 1 July 1995 (1995-07-01), pages 1731 - 1738, XP000647015, ISSN: 1350-0872 *
ROSCHIER MAARIA ET AL: "A differential display protocol to identify differentially expressed mRNAs in potassium-deprived cerebellar granule cells.", BRAIN RESEARCH PROTOCOLS, vol. 5, no. 2, April 2000 (2000-04-01), pages 121 - 131, XP001025685, ISSN: 1385-299X *
WANG SONGLI ET AL: "Genes induced in programmed cell death of neuronal PC12 cells and developing sympathetic neurons in vivo.", DEVELOPMENTAL BIOLOGY, vol. 188, no. 2, 1997, pages 322 - 336, XP002178542, ISSN: 0012-1606 *

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859741B2 (en) 2007-08-23 2014-10-14 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8871913B2 (en) 2007-08-23 2014-10-28 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8871914B2 (en) 2007-08-23 2014-10-28 Amgen, Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8883983B2 (en) 2007-08-23 2014-11-11 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8889834B2 (en) 2007-08-23 2014-11-18 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US9493576B2 (en) 2007-08-23 2016-11-15 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US8981064B2 (en) 2007-08-23 2015-03-17 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
US9266961B2 (en) 2012-06-15 2016-02-23 Genentech, Inc. Anti-PCSK9 antibodies, formulations, dosing, and methods of use
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9109034B1 (en) 2014-07-15 2015-08-18 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8999341B1 (en) 2014-07-15 2015-04-07 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9034331B1 (en) 2014-07-15 2015-05-19 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9062105B1 (en) 2014-07-15 2015-06-23 Kymab Limited Precision Medicine by targeting VEGF-A variants for treatment of retinopathy
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9187562B1 (en) 2014-07-15 2015-11-17 Kymab Limited Methods for treating anaemia
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9303089B2 (en) 2014-07-15 2016-04-05 Kymab Limited Methods of treating anaemia
US9394568B2 (en) 2014-07-15 2016-07-19 Kymab Limited Methods of treating anaemia
US9428578B2 (en) 2014-07-15 2016-08-30 Kymab Limited Methods of treating anaemia
US9439963B2 (en) 2014-07-15 2016-09-13 Kymab Limited Methods of treating anaemia
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R

Also Published As

Publication number Publication date
AU2001241461A1 (en) 2001-08-14
WO2001057081A2 (fr) 2001-08-09
EP1257572A2 (fr) 2002-11-20
CA2399727A1 (fr) 2001-08-09

Similar Documents

Publication Publication Date Title
WO2001057081A3 (fr) Nouveaux homologues de type subtilase (narc-1)
AU5608000A (en) 22025, a novel human cyclic nucleotide phosphodiesterase
WO2001032891A3 (fr) 188891, nouvelle lipase humaine
WO2002086076A3 (fr) Polynucleotides et polypeptides associes au chemin nf-kb
WO2002072751A3 (fr) Polynucleotides codant une nouvelle metalloprotease, mp-1
WO2004100886A3 (fr) Polynucleotides et polypeptides associes a la voie nf-kb
WO2002018576A3 (fr) Compositions et methodes associees aux genes specifiques du poumon
WO2001000811A8 (fr) Nouvelle aminopeptidase humaine (17867)
WO2001036605A3 (fr) 2786, nouvelle aminopeptidase humaine
WO2003027231A3 (fr) Polynucleotide codant pour une nouvelle proteine d'adaptation, pmn29, contenant le domaine d'homologie avec la pleckstrine et le domaine riche en proline
WO2001023590A3 (fr) La 22196, nouvelle aminopeptidase humaine
WO2001023589A3 (fr) Nouvelle ubiquitine protease humaine nommee 23431
WO2001064858A3 (fr) 25312, un nouvel homologue humain du type agmatinase
WO2001064880A3 (fr) La 40322, nouvelle dynamine humaine
WO2001000812A3 (fr) 22012, une nouvelle carboxypeptidase humaine
WO2001044446A3 (fr) Nouveaux alcools-deshydrogenases 21612, 21615, 21620, 21676, 33756
ATE348889T1 (de) 27411, eine menschliche phosphatidyl- glycerinphosphate (pgp) synthase
EP0812916A3 (fr) Gène de la cathepsin K
WO2001064887A3 (fr) Nouvelles protéines g humaines 32705, 23224, 27423, 32700, 32712
WO1999030670A3 (fr) Procedes de traitement utilisant de nouveaux ligands du recepteur hfgan72 de neuropeptides et leurs agonistes ou antagonistes
WO2001064873A3 (fr) Nouvelles proteines activatrices de gtpase humaines
WO2001059081A3 (fr) Procedes d'utilisation de 20893, une proteine kinase humaine
WO2002008278A3 (fr) Compositions et procedes relatifs aux genes specifiques aux poumons
IL155687A0 (en) Polynucleotides encoding hlrrsi1 polypeptides
WO2002000826A3 (fr) Nouveau polypeptide, proteine humaine de methylation d'adn, et polynucleotide codant ce polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2399727

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 557912

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001912710

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001912710

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001912710

Country of ref document: EP